Golden Agriculture: Chinese demand on the rise.

Price closed 1c lower at 57.5c today. The weakness is accompanied by a much reduced volume.  So, I am not too worried. Looking at the other indicators, we see the MFI forming a higher low, suggesting improving demand.  OBV is likewise rising, suggesting more robust accumulation activities.  The RSI has bounced off 50% which acted as support, suggesting a return of buying momentum. Any further weakness should see strong support at 55.5c as provided by the 100dMA.

The fundamentals are strong and the momentum oscillators are promising.  I would accumulate on weakness.

China's vegetable oil demand is entering a seasonal high, buoying edible oil and feedmeal prices, as the Mid-Autumn Festival and National Day holidays approach. 

"There is a supply reduction in oilseeds and this is leading to greater dependency on palm oil as supply growth is lagging behind demand," a senior trading executive at Malaysia-based major plantation company said. 

-By Shie-Lynn Lim, Dow Jones Newswires; +603 2026 1233; shie-lynn.lim@dowjones.com

Healthway Medical: Second quarter results.

Healthway Medical announced that it has entered into agreements with twelve (12) medical and dental centres in Shanghai and Hangzhou.  To operate and manage these facilities, an investment of RMB38m (or S$7.6m) is required over a period of three months. They hope to increase the number of facilities under management to more than twenty by end of this year.

At the same time, Healthway Medical also released their second quarter results and the numbers look bad.

1. Revenue compared to the same period last year has tumbled 12.3% from S$24.45m to S$21.44m.  This is worse than the first quarter when the revenue declined 6.3% compared to the same period a year ago.

2. Staff cost increased 22.9% which suggests that Healthway Medical is paying a lot more now to retain or to recruit staff.  In terms of absolute dollars, the increase from S$10.75m to S$13.2m is no small change.

3. Profit before income tax is an insignificant S$165k compared to S$5.23m in the same period last year.  This is much worse than the first quarter profit of S$1.4m.

4. Cash flow from operations is a negative S$2.3m compared to a positive S$4.05m in the same period last year.  However, it is an improvement over a negative S$4.94m in the last quarter.

5. Cash flow from financing activities is still a positive S$18.79m and the company has S$32.6m in bank deposits.

6. EPS for the quarter is 0.01c, down from 0.32c in the same quarter last year and down from 0.09c in the last quarter.

Fundamentally, Healthway Medical's numbers in the first quarter were relatively bad but they are now worse.  See second quarter statements here.

On 16 May, I blogged about Healthway Medical's first quarter results.  I said: "As an investor, to be prudent, I would continue to wait for greater clarity on whether higher earnings would follow, maintaining that the share price at current level does not offer good value."  This opinion has not changed.

Although Healthway Medical has taken another important step in its expansion plans in China, risks still exist and it remains to be seen if the management is able to execute its plans successfully and deliver value to shareholders.  With weakening revenue and rising costs at home and possible teething problems in China, investing in Healthway Medical at the current price is not for the faint hearted.

On 11 Aug, I blogged about how Healthway Medical's support at 18.5c has been compromised and that price could go lower. It is likely that 17c could be tested as a support sooner than later.

Related post:
Healthway Medical: A weak first quarter.
Healthway Medical: Support compromised.

Charts in brief: 13 Aug 10 (Part 3).

Noble: Looking at Noble's chart, the double top formation is quite obvious. If this is a valid formation, we could possibly see price declining to hit $1.20.  Top at $2.20, neckline at $1.70, target at $1.20.  A scary possibility? Price closed at $1.54, the low formed on 20 May.  Could this hold?  Well, the MFI just dipped into oversold territory.  RSI continues to sink in oversold territory.  OBV shows continuing distribution.  Price could enjoy a brief rebound and should meet with resistance at $1.64 in such an instance.

Noble cut to Hold by DBS Vickers with $1.62 target. DBS Vickers says 2Q10 results dismal, with earnings down 65% on year at US$86.6 million ($118 million).
Friday, 13 August 2010

© 2010 - The Edge Singapore

KGT: I am still interested in collecting some units of KGT.  However, the price refuses to fall below $1.10.  When I first blogged about KGT, it was at $1.06 and I said I would wait for $1.00.  Doesn't seem very probable now. However, I decided to sneak a peek at the charts. 

Well, not much to work on but notice that price has been trading below the 20dMA in recent sessions with a falling MACD. MFI has formed lower highs which suggests a falling demand. The RSI has likewise been falling suggesting increasing selling pressure over time. We could see KGT at under $1.10 again if this keeps up.  Good things come to those who wait?  Of course, if the counter goes CD soon, it could change everything.

Related post:
K-Green Trust: A stable source of passive income.

Cambridge Industrial Trust: Acquisitions and private placement.

CIT is acquiring new industrial properties in Singapore. The new purchases are to be at market valuations.

As CIT is already highly geared, to do this, it will have a private placement which will raise approximately S$37.6m, after deducting fees and expenses.  This will increase the number of units by 83,683,000. It has also secured new loan facilities, a S$50m term loan and a S$20m revolving credit from National Australia Bank Ltd.
 
By acquiring new assets valued at S$37.2m and going ahead with the private placement, CIT bumps up the value its total assets.  This is the reason why the total gearing level will reduce from 42.3% to 41.5%.

Of greater interest to existing unitholders is the effect of the acquisitions and private placement on their investment in CIT.  Will existing unitholders see greater income flow from their current investment in CIT?

Due to the acquisitions, total distributable income is expected to increase 5.7%.  However, in order to fund the acquisitions, the private placement would lead to an increase of 10.15% of units in issue.  This effectively dilutes the DPU of CIT, post acquisition. DPU is estimated to fall from 5.36c to 5.14c.  NAV per unit will also fall from 60c to 58c.

I continue to believe that AIMS AMP Capital Industrial REIT is a better investment than CIT in the world of industrial S-REITs.  The former has a stronger balance sheet and a bigger discount to NAV.  Although its yield is lower at 9.55% based on a unit price of 22.5c, it has greater room to gear up to make yield accretive acquisitions. Chances of a dilutive exercise like this one by CIT are therefore lower.

Read announcement here.

Related post:
AIMS AMP Capital Industrial REIT: Steady performance.